Lung cancer: New approaches to screening and diagnosis

Produced by OHSU Knight – Legacy Health Cancer Collaborative


Wednesday, April 29


Portland Marriott Downtown Waterfront
Columbia and Willamette Rooms, first floor
1401 S.W. Naito Parkway
Portland, OR 97201

Who should attend:

Primary care providers, family medicine, internal medicine and other health care providers.

Registration deadline:

April 27, 2015

Register now

Learning objectives

  1. Knowledge and understanding of lung cancer screening criteria (who to screen and who not to screen)
  2. Understanding of the basis for lung cancer screening, and the importance of lung cancer screening as part of a multidisciplinary lung cancer program
  3. To learn about the growing variety of actionable mutations in NSCLC
  4. To understand how next-generation sequencing can be used to identify new treatment options

Conference schedule

Wednesday, April 29, 2015

5:30–6 p.m.       
Registration, hosted wine bar and buffet dinner

6–6:15 p.m.
Welcome and introduction

Tony Melaragno, M.D.
Vice President,
Oncology and Behavioral Health,
Legacy Health

Robert Raish, M.D.
OHSU Knight Cancer Institute,
Community Hematology Oncology,
OHSU Knight–Legacy Health Cancer Collaborative

6:15–7 p.m.       
Lung Cancer Screening: A Paradigm Shift in Lung Cancer Care

This talk will review the background and basis for lung cancer screening, identify the patient characteristics (eligibility criteria) for lung cancer screening, cover technical aspects of lung cancer screening and reporting, review the required elements of a lung cancer screening program, and address insurance coverage including recent CMS guidelines.

Jordan Fein, M.D.
Pulmonologist and medical director
Legacy Thoracic Oncology Program

7–7:45 p.m.       
Molecular subtyping non-small cell carcinoma: The role of next-generation sequencing

This talk will review the major driver mutations in non-small cell lung cancer, how next-generation sequencing can be used to identify them and how they are being targeted with new therapies.

Christopher Corless, M.D., Ph.D.
Executive director and chief medical officer
Knight Diagnostic Laboratories
OHSU Knight Cancer Institute

7:45–8 p.m.       
Questions and answers


Oregon Health & Science University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

OHSU School of Medicine, Division of CME designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.